Interstitial Lung AbnormalitiesSSILANCT07023575
Study on Screening Strategies for Interstitial Lung Abnormalities and Airway Lesions
An observational study of Interstitial Lung Abnormalities, run by China-Japan Friendship Hospital at 10 sites in China.
Trial summary
The goal of this observational study is to learn about the comorbidity patterns of interstitial and airway abnormalities in adults undergoing health examinations in China. The main questions it aims to answer are: How do early interstitial lung abnormalities progress to comorbid interstitial and airway diseases? What… Read more about this study
- Who is it for?
- Ages 40 years and olderHealthy volunteers can take part
- Conditions the study is for
- Interstitial Lung Abnormalities
- How many people
- 100,000 participants
- Where
- 10 sitesChina
- Study dates
- 1 Aug 2025to 30 Nov 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Participants were recruited from multiple health checkup centers across various regions of China between 2017 and 2024. Specifically, this retrospective study included data from 10 hospital-based health examination institutions located within the four major economic regions of China (East, Central, West, and Northeast). All available health examination records of individuals who underwent chest CT scans during this period were collected for analysis.
Who may be able to join
- Underwent chest CT examination between January 1, 2017 and December 31, 2024
- Age 18 years or older at the time of examination
Who cannot join
- Missing or incomplete key demographic or imaging information (e.g., missing date of examination, sex, age, or CT report)
Trial locations and contacts
10 sites in 1 country. Contact the study team or a site near you to ask about taking part.
10 sites in 1 country
China10 sites
China-Japan Friendship Hospital
Beijing, Beijing Municipality
Xianhui Ran, PhD, 8613162906826, xhran1995@163.com
Zhongguancun Meinian Health Industry Research Institute
Beijing
Central South University
Changsha
Fang Liu, 0731-89753199, xyliufang@csu.edu.cn
Affiliated Hospital of Guizhou Medical University
Guiyang
Lan Mo, 0851-86810999, 648047585@qq.com
Zhejiang University
Hangzhou
Jiaojiao Huang, 571-87784679, 2522113@zju.edu.cn
Henan Provincial People's Hospital
Henan
Shaobo Duan, 86-0371-65580321, dustin2662@163.com
The Affiliated Hospital of Qingdao University
Qingdao
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality
86-021-64038038, dreamingkoala@126.com
The First Affiliated Hospital of China Medical University
Shenyang
Zixiao Wang, 86-024-83283107, 876856868@qq.com
Henan Hongli Hospital Co., Ltd
Xinxiang
Lei Yang, 0373-8882111, yanglyl111@126.com
About this study
The goal of this observational study is to learn about the comorbidity patterns of interstitial and airway abnormalities in adults undergoing health examinations in China. The main questions it aims to answer are:
How do early interstitial lung abnormalities progress to comorbid interstitial and airway diseases? What are the key factors associated with this progression?
Participants undergoing routine health examinations will be assessed for interstitial and airway abnormalities based on imaging and clinical data. Longitudinal follow-up will be used to evaluate disease progression and identify associated risk factors.
- Conditions
- Interstitial Lung Abnormalities
- Keywords
- interstitial lung abnormalities
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Chinese Routine Chest CT Health Examination Cohort | This group includes individuals who underwent routine health examinations with chest CT imaging at participating health checkup centers across China between 2017 and 2024. Participants may have one or more CT records, and no interventions were applied as part of the study. This group will be analyzed for the presence of interstitial lung abnormalities and/or airway diseases based on imaging and lung function data, as well as demographic and clinical characteristics. |
What is being measured
The primary outcome is the main question the study is designed to answer.
high-resolution computed tomography (HRCT) examinations
Measured: through study completion, an average of 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Jun 2025
- Study start1 Aug 2025 (estimated)
- Primary completion30 Nov 2028 (estimated)
- Study completion30 Nov 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Interstitial Lung AbnormalitiesStudies of the same condition, open and under way.
- More trials run by China-Japan Friendship HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 100,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- China-Japan Friendship Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ma Xiao, China-Japan Friendship Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07023575
- Sponsor's protocol ID
- 2024ZD0522301
- Acronym
- SSILA
- Status last verified
- Jun 2025
- First submitted
- 8 Jun 2025
- Last updated
- 17 Jun 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Study on Screening Strategies for Interstitial Lung Abnormalities and Airway Lesions
- ClinicalTrials.gov ID
- NCT07023575
- Acronym / sponsor ID
- SSILA / 2024ZD0522301
- Conditions
- Interstitial Lung Abnormalities
- Keywords
- interstitial lung abnormalities
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 100,000 participants (estimated)
- Lead sponsor
- China-Japan Friendship HospitalUniversity, hospital or other
- Study start
- 1 Aug 2025 (estimated)
- Primary completion
- 30 Nov 2028 (estimated)
- Study completion
- 30 Nov 2028 (estimated)
- First posted
- 17 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to learn about the comorbidity patterns of interstitial and airway abnormalities in adults undergoing health examinations in China. The main questions it aims to answer are:
How do early interstitial lung abnormalities progress to comorbid interstitial and airway diseases? What are the key factors associated with this progression?
Participants undergoing routine health examinations will be assessed for interstitial and airway abnormalities based on imaging and clinical data. Longitudinal follow-up will be used to evaluate disease progression and identify associated risk factors.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Chinese Routine Chest CT Health Examination Cohort | – | –This group includes individuals who underwent routine health examinations with chest CT imaging at participating health checkup centers across China between 2017 and 2024. Participants may have one or more CT records, and no interventions were applied as part of the study. This group will be analyzed for the presence of interstitial lung abnormalities and/or airway diseases based on imaging and lung function data, as well as demographic and clinical characteristics. |
Who may qualify
- Ages
- 40 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Participants were recruited from multiple health checkup centers across various regions of China between 2017 and 2024. Specifically, this retrospective study included data from 10 hospital-based health examination institutions located within the four major economic regions of China (East, Central, West, and Northeast). All available health examination records of individuals who underwent chest CT scans during this period were collected for analysis.
Key inclusion criteria (2 listed)
- Underwent chest CT examination between January 1, 2017 and December 31, 2024
- Age 18 years or older at the time of examination
Key exclusion criteria (1 listed)
- Missing or incomplete key demographic or imaging information (e.g., missing date of examination, sex, age, or CT report)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
high-resolution computed tomography (HRCT) examinations
Time frame: through study completion, an average of 1 year
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Jun 2025.
- Individual participant dataSharing planned: No
Related trials for Interstitial Lung Abnormalities
RecruitingPhase 3
A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis
Familial Pulmonary Fibrosis, Interstitial Lung Abnormalities
Active, not recruitingPhase 2
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Advanced Malignant Solid Neoplasm, Malignant Solid Neoplasm
RecruitingObservational study
Role of Genetic Factors in the Development of Lung Disease
Cystic Fibrosis, Pulmonary Fibrosis
Active, not recruitingObservational study
Analysis of Specimens From Individuals With Pulmonary Fibrosis
Pulmonary Fibrosis, Healthy Volunteers
Active, not recruitingPhase 2
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
10 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Interstitial Lung Abnormalities, run by China-Japan Friendship Hospital at 10 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 17 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 10 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
high-resolution computed tomography (HRCT) examinations (time frame: through study completion, an average of 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jun 2025.